Alembic, Aurobindo recall drugs in US market
Alembic Pharmaceuticals and Aurobindo Pharma are recalling products in the US due to manufacturing problems. Alembic is recalling 82,400 bottles of Tobramycin Ophthalmic Solution due to “Failed Impurities/Degradation Specifications.” Meanwhile, Aurobindo Pharma is recalling 48 bottles of Rufinamide Tablets, in both 200 mg and 400 mg doses, due to cGMP (current good manufacturing practice) deviations, USFDA said. The batch was released prior to approval. Rufinamide tablets are u sed to treat seizure disorders. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 21, 2023 Category: Pharmaceuticals Source Type: news
Glenmark Pharma launches anti-epileptic drug, Rufinamide, in the US
The newly launched drug is a therapeutic equivalent of Banzel tablets, 200 mg and 400 mg of Eisai, Inc. Banzel tablets are used in combination with other medications to treat children with Lennox-Gastaut syndrome, a severe form of childhood epilepsy that also causes developmental and behavior problems. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 1, 2021 Category: Pharmaceuticals Source Type: news
Organic synthesis in a modular robotic system driven by a chemical programming language
The synthesis of complex organic compounds is largely a manual process that is often incompletely documented. To address these shortcomings, we developed an abstraction that maps commonly reported methodological instructions into discrete steps amenable to automation. These unit operations were implemented in a modular robotic platform by using a chemical programming language that formalizes and controls the assembly of the molecules. We validated the concept by directing the automated system to synthesize three pharmaceutical compounds, diphenhydramine hydrochloride, rufinamide, and sildenafil, without any human intervent...
Source: ScienceNOW - January 10, 2019 Category: Science Authors: Steiner, S., Wolf, J., Glatzel, S., Andreou, A., Granda, J. M., Keenan, G., Hinkley, T., Aragon-Camarasa, G., Kitson, P. J., Angelone, D., Cronin, L. Tags: Chemistry, Online Only r-articles Source Type: news
Banzel (Rufinamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 2, 2017 Category: Drugs & Pharmacology Source Type: news
Rufinamide (Rufinamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 15, 2016 Category: Drugs & Pharmacology Source Type: news
Glenmark gets final nod by USFDA to sell Rufinamide drug
Rufinamide is used to treat seizures caused by Lennox-Gastaut syndrome, it will be available as tablets in 200 mg and 400 mg strengths. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 19, 2016 Category: Pharmaceuticals Source Type: news
Glenmark gets tentative USFDA nod to sell Rufinamide
Glenmark Pharmaceuticals today said it has been granted tentative approval by the US health regulator to sell Rufinamide. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 21, 2015 Category: Pharmaceuticals Source Type: news
Japan's Eisai receives FDA expanded approval for antiepileptic drug Banzel
Japanese pharmaceutical company Eisai has received expanded approval from the US Food and Drug Administration (FDA) for its antiepileptic drug (AED), Banzel (rufinamide) to treat children and infants. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 16, 2015 Category: Pharmaceuticals Source Type: news
Efficacy and Safety of Rufinamide in Pediatric EpilepsyEfficacy and Safety of Rufinamide in Pediatric Epilepsy
Rufinamide, a novel anticonvulsant approved for the treatment of seizures associated with Lennox-Gastaut syndrome, is proving to be a valuable treatment option in pediatric epilepsy. Therapeutic Advances in Neurological Disorders (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 15, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
